康华生物:2024年报净利润3.99亿 同比下降21.61%

Financial Performance - The company's basic earnings per share decreased by 20.47% to 3.0279 yuan in 2024 from 3.8073 yuan in 2023 [1] - Net profit fell by 21.61% to 3.99 billion yuan in 2024 compared to 5.09 billion yuan in 2023 [1] - Operating revenue declined by 9.19% to 14.32 billion yuan in 2024 from 15.77 billion yuan in 2023 [1] - The return on equity decreased by 23.87% to 11.64% in 2024 from 15.29% in 2023 [1] - The net asset per share slightly decreased by 0.65% to 25.93 yuan in 2024 from 26.1 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 49.22 million shares, accounting for 40.86% of the circulating shares, with a decrease of 7.2829 million shares compared to the previous period [2] - The largest shareholder, Aokang Group Co., Ltd., holds 16.3055 million shares, representing 13.53% of the total share capital, with no change [3] - Jinan Kangyue Qiming Investment Partnership reduced its holdings by 280,300 shares, now holding 9.7197 million shares, which is 8.07% of the total [3] - New entrants among the top shareholders include a securities investment fund holding 8.079 million shares, accounting for 6.70% [3] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share (including tax) [4]